Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Fried

Showing results (11-20 of 166) with videos related to

Pageof 17
Sort By:
Clinics in Liver Disease|December 14, 2006
Optimizing treatment regimens in hepatitis CJama M Darling, Michael W Fried
Gastroenterology|April 28, 2012
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusA Sidney Barritt, Michael W Fried
Current Gastroenterology Reports|January 15, 2004
Guidelines for stopping therapy in chronic hepatitis CMark W Russo, Michael W Fried
Clinics in Liver Disease|April 15, 2003
Current therapy for hepatitis C: pegylated interferon and ribavirinJohn G McHutchison, Michael W Fried
Gastroenterology|May 23, 2003
Side effects of therapy for chronic hepatitis CMark W Russo, Michael W Fried
Clinical Liver Disease|June 13, 2019
Hepatitis C viral infection in patients with hemophilia and hemolytic disordersEric S Orman, Michael W Fried
Clinical Liver Disease|June 13, 2019
Controversies in hepatitis C therapy: Reactivation of hepatitis B virusSarah R Lieber, Michael W Fried
Hepatology (Baltimore, Md.)|February 13, 2018
Parsing the guidelines on guidelines: Balancing sensibility and conflict of interestStephen D Zucker, Michael W Fried
Gastroenterology|January 27, 2009
Nitazoxanide: beyond parasites toward a novel agent for hepatitis CJama M Darling, Michael W Fried
Hepatology (Baltimore, Md.)|March 5, 2013
The FDA, bridging data, and hepatitis CMichael W Fried, Donald M Jensen
Pageof 17

Showing results (11-20 of 166) with videos related to

Sort By:
Pageof 17
Clinics in Liver Disease|December 14, 2006
Optimizing treatment regimens in hepatitis CJama M Darling, Michael W Fried
Gastroenterology|April 28, 2012
Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusA Sidney Barritt, Michael W Fried
Current Gastroenterology Reports|January 15, 2004
Guidelines for stopping therapy in chronic hepatitis CMark W Russo, Michael W Fried
Clinics in Liver Disease|April 15, 2003
Current therapy for hepatitis C: pegylated interferon and ribavirinJohn G McHutchison, Michael W Fried
Gastroenterology|May 23, 2003
Side effects of therapy for chronic hepatitis CMark W Russo, Michael W Fried
Clinical Liver Disease|June 13, 2019
Hepatitis C viral infection in patients with hemophilia and hemolytic disordersEric S Orman, Michael W Fried
Clinical Liver Disease|June 13, 2019
Controversies in hepatitis C therapy: Reactivation of hepatitis B virusSarah R Lieber, Michael W Fried
Hepatology (Baltimore, Md.)|February 13, 2018
Parsing the guidelines on guidelines: Balancing sensibility and conflict of interestStephen D Zucker, Michael W Fried
Gastroenterology|January 27, 2009
Nitazoxanide: beyond parasites toward a novel agent for hepatitis CJama M Darling, Michael W Fried
Hepatology (Baltimore, Md.)|March 5, 2013
The FDA, bridging data, and hepatitis CMichael W Fried, Donald M Jensen
Pageof 17